At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metformin for Preventing Frailty in High-risk Older Adults
In Brief
A Phase 2 clinical trial evaluating Metformin and Placebo for Frailty. Completed, enrolled 141 participants across 1 site.
Detailed Summary
Frailty is a geriatric syndrome which leads to poor health outcomes in older adults, such as falls, disability, hospitalization, institutionalization, and death. Due to the dramatic growth in the U.S. aging population and the health care costs associated with frailty (estimated at more than $18 billion per year), frailty is a major health care problem. There has been little research into potential pharmacologic interventions that would delay or reduce the incidence of frailty. Thus, the major goal of this study is to test metformin as a novel intervention for the prevention of frailty. The investigators propose that diabetes/insulin resistance and inflammation are major contributors to frailty, and that the use of metformin to modulate diabetes/insulin resistance and inflammation will prevent and/or ameliorate the progression of frailty.
Study Details
Timeline
Interventions
Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
Subjects will randomized to placebo will receive placebo